Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fenretinide (CerRx)
- Development stage
- Unknown
- Lead developer
- SciTech Development
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Fenretinide is a synthetic retinoid derivative (N-(4-hydroxyphenyl)retinamide) developed by CerRx, Inc. for the treatment of various cancers, most notably peripheral T-cell lymphoma (PTCL). Its mechanism of action is distinct from other retinoids; while it can bind to retinoic acid receptors, its primary cytotoxic effect is driven by the induction of reactive oxygen species (ROS) and the accumulation of intracellular ceramide, which leads to apoptosis in malignant cells. CerRx developed a proprietary intravenous emulsion formulation to bypass the absorption limitations and low bioavailability of oral fenretinide. This IV formulation was evaluated in Phase II clinical trials for patients with relapsed or refractory PTCL.
- Other names
- N-(4-hydroxyphenyl)retinamideIV Fenretinidefenretinide emulsion
02
Targets
DEGS1 (Delta(4)-desaturase, sphingolipid 1)RARA (Retinoic acid receptor alpha)RARB (Retinoic acid receptor beta)RARG (Retinoic acid receptor gamma)RBP4 (Retinol-binding protein 4)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on fenretinide (CerRx).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fenretinide (CerRx).